alpha-conotoxin imi has been researched along with Lung Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, B; Mei, D; Ni, X; Wang, X; Yu, Z; Zhang, Q; Zhang, X; Zhao, L | 1 |
| Cattaneo, MG; Clementi, F; Codignola, A; McIntosh, JM; Sher, E; Vicentini, LM | 1 |
2 other study(ies) available for alpha-conotoxin imi and Lung Neoplasms
| Article | Year |
|---|---|
α-Conotoxin ImI-modified polymeric micelles as potential nanocarriers for targeted docetaxel delivery to α7-nAChR overexpressed non-small cell lung cancer.
Topics: A549 Cells; alpha7 Nicotinic Acetylcholine Receptor; Animals; Carcinoma, Non-Small-Cell Lung; Conotoxins; Docetaxel; Dose-Response Relationship, Drug; Drug Carriers; Drug Delivery Systems; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Micelles; Nanocapsules; Polymers; Random Allocation; Taxoids | 2018 |
alpha-Conotoxin imperialis I inhibits nicotine-evoked hormone release and cell proliferation in human neuroendocrine carcinoma cells.
Topics: Carcinoma, Small Cell; Cell Division; Conotoxins; Hormones; Humans; Lung Neoplasms; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Oligopeptides; Receptors, Nicotinic; Tumor Cells, Cultured | 1996 |